Dr Reddy's Laboratories
announced the launch of Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the US Food and Drug Administration (USFDA).
The Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets brand and generic had US sales of approximately $44 mn MAT for the most recent twelve months ending in May 2019 according to IRi. Dr. Reddy's OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP are available in 20- and 30-count sizes.
Dr. Reddy's OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP, are used for temporary relief of symptoms due to hay fever or other upper respiratory allergies that include runny nose, sneezing; itchy, watery eyes; itching of the nose or throat.
"We are pleased to be expanding our pseudoephedrine-based product offering in time for the cough, cold and allergy season". "We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers," Milan Kalawadia, Senior Vice President and Head of US OTC and Specialty Rx Divisions, Dr. Reddy's Laboratories said.
Dr Reddys Laboratories Ltd is currently trading at Rs2,633.15, down by Rs22.35 or 0.84% from its previous closing of Rs2,655.50 on the BSE.
The scrip opened at Rs2,670 and has touched a high and low of Rs2,679.55 and Rs2,620.10 respectively.